Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's fourth quarter 2023 financial results on Tuesday, March 12, 2024, after the close of the U.S. financial markets.

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024 being held in Miami, Florida on March 11-13, 2024.

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos' Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023. The presentations can be found on the “Scientific Presentations & Conferences” section of the Aligos website (www.aligos.com).

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. ET.

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Aligos Therapeutics (NASDAQ:ALGS) stock is falling on Monday after the clinical-stage biopharmaceutical company announced plans for a porposed public share offering. According to a filing with the Securities and Exchange Commission (SEC), the selling stockholders are preparing to offer as many as 168,725,925 shares of ALGS stock.

Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?

The thyroid hormone receptor-beta ( THR- b) drug ALG-055009: Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study in hypercholesterolemic subjects Demonstrated favorable PK with low variability Dose responsively lowered lipid levels in study subjects Was well tolerated in animals following repeated daily dosing in 13 week toxicology studies Is more b selective and 5-47x more potent than resmetirom and VK-2809 parent Has a favorable overall risk-benefit profile which supports conducting a 12-week Phase 2a study in NASH subjects SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that clinical and nonclinical data for its thyroid hormone receptor-beta (THR-b) drug, ALG-055009, were presented Saturday, November 11th at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023.

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated:

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

November 16 Event to feature KOL perspective on Emerging HBV Therapies November 16 Event to feature KOL perspective on Emerging HBV Therapies

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the third quarter 2023.

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results

Proceeds expected to fund the following: - NASH (ALG-055009): top line data from Phase 2a study (Q4 2024) - Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024) - Funding expected to extend cash runway through end of 2025

Aligos Therapeutics Announces $92 Million Private Placement Financing

- NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies

Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 - Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

- Phase 1 study conduct complete with preliminary data indicating THR-beta agonist ALG-055009 was well-tolerated with a favorable PK profile and dose responsive changes in relevant biomarkers

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks-

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. (“Amoytop”) for the use of Aligos' oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.84 per share a year ago.

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the first quarter 2023.

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.

Aligos Therapeutics to Announce First Quarter Results on May 4, 2023

SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023. The presentations will be available on the Scientific Presentations and Conferences page on Aligos' corporate website following the meeting.

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company presented Phase 1 data for its thyroid receptor-beta (THR-ß) agonist candidate, ALG-055009, at the 15th Paris Hepatology Conference, taking place virtually March 27 – 29, 2023. The presentation will be available on the Scientific Presentations and Conferences page on Aligos' corporate website following the meeting.

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Aligos Therapeutics Stock (ALGS)